LYMPHOMA

This early-stage study is testing a new type of CAR-T cell therapy for people with B-cell blood cancers (like certain leukemias and lymphomas) that have come back or stopped responding to standard treatments. The therapy uses donor immune cells that are specially designed to find…

This early-phase study tests a new type of cell therapy for people with certain cancers (lymphoma, myeloma, and solid tumors like kidney cancer and sarcoma) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified …

This study tests a combination of three targeted drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first treatment for people with aggressive B-cell lymphomas. The goal is to see if this chemo-free approach can shrink tumors effectively while causing fewer side effect…

This study tests a combination of two drugs—nemtabrutinib and rituximab—for people with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo can shrink or eliminate tumors. About 35 adults will take part. The approach aims to control the disease, n…

This early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a missing MTAP gene. The main goals are to find a safe dose and see how the drug works in the body. About 186 adults will take part, and the study will also check if …

This study tests a stem cell transplant approach for people with blood cancers caused by an inherited RUNX1 gene mutation. The goal is to see if customizing chemotherapy and supportive care doses for each patient improves disease-free survival compared to standard transplant outc…

This study tests a new drug called BT02 in people with blood cancers (leukemia, lymphoma, or multiple myeloma) that have returned or not responded to treatment. About 116 adults aged 18 to 70 will receive the drug by IV every 2-3 weeks for up to 2 years. The main goals are to che…

This early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) in 18 adolescents and young adults aged 12–30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is…

This early-stage study tests a new type of CAR-T cell therapy that is made inside the body, avoiding the expensive and complex lab process normally needed. It targets two proteins (CD19 and BAFF-R) on cancer cells in people with relapsed or hard-to-treat B-cell acute leukemia or …

This study tests whether the drug sotagliflozin can prevent heart, muscle, and fat damage caused by a common type of chemotherapy (anthracycline) in people with newly diagnosed lymphoma. About 60 participants will receive either the drug or a placebo during their first round of c…

This study tests whether a mind-body resilience group program can help lymphoma survivors better cope with challenges after finishing treatment. About 254 adults who completed lymphoma treatment within the past two years will participate. The program focuses on relaxation, recogn…

This study tests whether a resilience-building program can improve quality of life for lymphoma survivors who finished treatment within the last two years. About 254 adults will take part, comparing the resilience program to a health education program. The goal is to see if learn…

This study looks at PET-CT scan results in people aged 60 and older who have lymphoma. The goal is to learn more about how the disease appears on these scans, which could help doctors make more accurate diagnoses and predictions. About 63 participants will be enrolled, and the st…

This study will create a structured follow-up program for 400 children and young adults who have survived blood cancers like leukemia and lymphoma. The goal is to better track and manage long-term health problems that can appear years after treatment. Researchers will use an elec…

This study will collect medical information from 1,000 people newly diagnosed with lymphoma. Researchers will track how long patients live without the disease getting worse and overall survival. The goal is to learn which treatments work best in real-world settings.

This study tests if a small, wearable patch called TempTraq can catch fevers early in cancer patients getting immunotherapy. Fevers can be a sign of cytokine release syndrome (CRS), a serious side effect. The patch monitors temperature continuously, which may help doctors act fas…

This study will follow 5,000 adults who have immune system problems (like inflammation or autoimmune disease) to see how often they also develop blood disorders, including a rare condition called VEXAS syndrome. Researchers will track new cases over time to better understand the …

This study looks at how a personalized strength training program affects people with different cancers (lung, colon, breast, lymphoma, and leukemia). 150 adults will either do supervised strength training plus home exercises, or just home exercises, for 12 weeks. Researchers will…